CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
Hypofractionated intensity modulated radiotherapyradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04580446
NCT04580446Phase 1Completed
CompareCT.gov

HYHOPE: Phase I Study of De-intensified Hypofractionated Radiation Therapy for Human Papilloma Virus-associated Oropharynx Cancer

University of Texas Southwestern Medical Center·interventional·Posted Oct 8, 2020·Updated Dec 15, 2025

In Brief

A Phase 1 clinical trial evaluating Hypofractionated intensity modulated radiotherapy for Human Papillomavirus-Related Carcinoma and Oropharyngeal Cancer. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This is a single arm Phase I study of de-intensified hypofractionated radiation therapy for favorable human papilloma virus-associated oropharynx cancer. It will evaluate the tolerability of a de-intensified hypofractionated radiation therapy regimen completed in 3 weeks (with equivalent biologically effective dose to 60 Gy in 30 fractions) with concurrent weekly cisplatin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Papillomavirus-Related Carcinoma, Oropharyngeal Cancer
CountriesUnited States
CollaboratorsGateway for Cancer Research

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedOct 8, 2020
Enrollment StartDec 3, 2020
Primary CompletionDec 20, 2024
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 5.7 years ago

Interventions

Hypofractionated intensity modulated radiotherapyradiation

Hypofractionated intensity modulated radiotherapy with concurrent chemotherapy (weekly cisplatin)